Briefing: Fresh turmoil at the FDA with Prasad’s exit — Digital Frequencies

← SIGNALS[LIFE]
Briefing: Fresh turmoil at the FDA with Prasad’s exitStrategic angle: Prasad out again, generic Ozempic on its way, and more health news from Morning Rounds
Editorial Staff / March 9, 2026 / 1 MIN READ

Summary

Summary pending editorial review.

Key Facts

Key facts pending editorial review.

Sources

STAT: https://www.statnews.com/2026/03/09/health-news-fresh-turmoil-at-the-fda-with-prasad-exit/?utm_campaign=rss